Market Research Report
Global Human Microbiome Therapeutics Market 2018-2022
|Published by||TechNavio (Infiniti Research Ltd.)||Product code||599236|
|Published||Content info||106 Pages
Delivery time: 1-2 business days
|Global Human Microbiome Therapeutics Market 2018-2022|
|Published: December 27, 2017||Content info: 106 Pages||
Microbiome Therapeutics is developing evidence-based microbiome modulators designed to shift bacterial populations and their environment in the gastrointestinal (GI) tract to better manage serious health conditions. GIT is an organ system that includes the mouth, esophagus, stomach, and the intestines. The GIT can be divided into upper Git and lower GIT. Upper GIT consists of the oral cavity, the pharynx, the esophagus, the stomach, and the duodenum. The lower GIT consists of the small and large intestines. Gastrointestinal disorders refer to diseases involving the GIT. Microbiome therapeutics are being increasingly adopted for the treatment of gastrointestinal disorders such as IBS and ulcerative colitis.
Technavio's analysts forecast the global human microbiome therapeutics market to grow at a CAGR of 14.19% during the period 2018-2022.
The report covers the present scenario and the growth prospects of the global human microbiome therapeutics market for 2018-2022. To calculate the market size, the report considers the revenue generated from the sales of human microbiome therapeutics.
The market is divided into the following segments based on geography:
Technavio's report, Global Human Microbiome Therapeutics market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.